Streptomycetes represent an important reservoir of active secondary metabolites with potential applications in the pharmaceutical industry. The gene clusters responsible for their production are often cryptic under laboratory growth conditions. Characterization of these clusters is therefore essential for the discovery of new microbial pharmaceutical drugs. Here, we report the identification of the previously uncharacterized nybomycin gene cluster from the marine actinomycete Streptomyces albus subsp. chlorinus through its heterologous expression. Nybomycin has previously been reported to act against quinolone-resistant Staphylococcus aureus strains harboring a mutated gyrA gene but not against those with intact gyrA. The nybomycin-resistant mutants generated from quinolone-resistant mutants have been reported to be caused by a back-mutation in the gyrA gene that restores susceptibility to quinolones. On the basis of gene function assignment from bioinformatics analysis, we suggest a model for nybomycin biosynthesis.
Introduction
Actinobacteria represent a prominent source of natural products with potential industrial applications. The genus Streptomyces is especially well known to produce a diverse spectrum of compounds with antibacterial, antifungal, antitumor and even insecticide and herbicide activity [1] [2] [3] . The increasing amount of sequenced microbial genomes has provided insight into the unprecedented potential of actinobacteria to biosynthesize natural products [4, 5] . Generally, dozens of various secondary metabolite clusters are encoded in their genomes. However, these clusters are often poorly expressed under standard cultivation conditions or even remain silent, thus preventing the isolation and characterization of the encoded compounds. Such uncharacterized clusters with unknown biosynthetic products are usually regarded as cryptic. Different approaches can be used to characterize cryptic clusters, including changing cultivation parameters (OSMAC approach), expression of pleiotropic regulatory genes, introduction of antibiotic-resistant mutations, and refactoring of the biosynthetic pathways [6] [7] [8] [9] . Currently, characterization of the cryptic gene clusters encoding natural products often relies on expression of their biosynthetic pathways in the optimized surrogate strains called heterologous hosts or chassis strains. The heterologous expression approach has a number of advantages compared to other cluster characterization methods. The simplified metabolic background of the chassis strains facilitates the identification of natural products; fast DNA-recombineering methods in E. coli and DNA transfer methods into streptomycetes simplify biosynthetic studies, and high production yields enable product supply for structure elucidation and biological activity studies.
In this study, we report the identification and characterization of the previously uncharacterized nybomycin gene cluster from the marine strain Streptomyces albus subsp. chlorinus NRRL B-24108 through heterologous expression in Streptomyces albus Del14. Nybomycin was first isolated in 1955; however, the unique biological activity of the antibiotic was discovered only recently [10] . Nybomycin inhibits growth of quinolone-resistant Staphylococcus aureus by targeting the mutated enzyme gyrase. Interestingly, the intact gyrase encoded by the gyrA gene without the resistance mutation is not inhibited by the antibiotic. The rare nybomycin-resistant mutants derived from quinolone-resistant S. aureus have all been reported to contain the reverse mutation in the gyrA gene, causing loss of quinolone resistance. Despite this interesting mode of action, the biosynthetic gene cluster leading to nybomycin production remains unknown. Based on the cluster analysis, we also propose the biosynthetic route leading to the production of nybomycin.
Results

Identification of the Nybomycin Gene Cluster through Its Heterologous Expression
In the course of systematic activation of cryptic secondary metabolite clusters from Streptomyces albus subsp. chlorinus NRRL B-24108 [3] , a cluster annotated by the antiSMASH genome mining software [11] as "fatty acid metabolism cluster" was expressed in the heterologous host strains. For this purpose, a BAC 4N24 containing the cluster was isolated from the previously constructed genomic library of S. albus subsp. chlorinus and transferred into Streptomyces albus Del14 and Streptomyces lividans TK24 [12, 13] . The obtained exconjugant strains Streptomyces albus 4N24 and Streptomyces lividans 4N24 as well as the corresponding control strains without the BAC S. albus Del14 and S. lividans TK24 were fermented in the production medium. LC-MS analysis of the exconjugant strains containing the heterologous cluster confirmed its successful expression in S. albus 4N24, as indicated by a new peak that was observed in the extract of the strain ( Figure 1A ,B and Figure S1 ). Expression of the cluster in S. lividans 4N24 did not lead to the production of any new compounds compared with the control strain. natural products; fast DNA-recombineering methods in E. coli and DNA transfer methods into streptomycetes simplify biosynthetic studies, and high production yields enable product supply for structure elucidation and biological activity studies.
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Discussion
The antibiotic nybomycin was discovered in 1955 in the culture broth of streptomycetes A 717 [14] . The structural features of nybomycin as a fused pyridoquinolone ring system and an angularly fused oxazoline ring are of particular biosynthetic interest as they have not been reported for other natural products [15] . Despite the unique structure of nybomycin, its biosynthetic cluster and biosynthetic route have remained elusive. Only the results of feeding studies imply that acetate, methionine, and some non-identified shikimate-type intermediates serve as biosynthetic precursors for nybomycin [15, 16] . In this article, we have described the identification of the nybomycin biosynthetic gene cluster from the marine streptomycete S. albus subsp. chlorinus NRRL B-24108 through its expression in the cluster-free heterologous host S. albus Del14.
Sequence analysis of the DNA fragment cloned in BAC 4N24 has revealed that a number of genes within this fragment are highly homologous to the genes involved in biosynthesis of the antibiotic streptonigrin (Table 1 ) [17] . Direct comparison of nybomycin and streptonigrin has shown distinct structural similarity, with both structures containing a diamino-substituted, six-membered ring (Figure 2) . The structural similarity and the partial homology of the gene clusters suggest that nybomycin and streptonigrin biosynthetic routes can have some similar biosynthetic intermediates and enzymatic reactions.
Based on the sequence analysis and the results of BAC expression, we propose that the genes nybA to nybZ constitute the nybomycin gene cluster. The nybA gene, encoding a putative 3-carboxy-cis, cis-muconate cycloisomerase, is homologous to the streptonigrin biosynthetic gene stnL. The nybZ gene encodes a putative transcriptional regulator that might also participate in nybomycin biosynthesis. Similar to the streptonigrin pathway, the 3-deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase encoded by nybF is likely to catalyze the first reaction in the nybomycin biosynthetic route. DAHP synthase is responsible for the first reaction of the shikimate pathway-biosynthesis of 3-deoxy-D-arabino-hept-2-ulosonate 7-phosphate (DAHP) from phosphoenolpyruvate and D-erythrose 4-phosphate (Figure 4) which is supported by the results of feeding experiments that have demonstrated that the carbons of the central ring of nybomycin are derived from a shikimate-type intermediate [15] . Catalyzing the first reaction, DAHP synthase regulates the amount of carbon entering the shikimate pathway and therefore can be responsible for its upregulation to provide sufficient amounts of biosynthetic precursors for nybomycin. The genes encoding enzymes responsible for the conversion of DAHP into chorismate are absent in the nybomycin cluster and in the streptonigrin pathway [17] . Therefore, the host's primary metabolism enzymes most likely overtake these biosynthetic steps. We propose that the second reaction catalyzed by the enzymes encoded in the biosynthetic cluster is the conversion of chorismate into 4-aminoanthranilic acid (Figure 4 ), which is a key intermediate in both nybomycin and streptonigrin biosynthesis (Figure 2) . Isolation of 4-aminoanthranilic acid from the culture broth of the streptonigrin producer Streptomyces flocculus supports this suggestion [18] . Furthermore, 4-aminoanthranilic acid has also been shown to incorporate into streptonigrin [18] . We propose that the products of the nybC, nybD, nybE, and nybL genes might be responsible for the conversion of chorismate into 4-aminoanthranilic acid. The nybL gene, encoding putative amidohydrolase [19] , has no homologue in the streptonigrin biosynthetic pathway. We suggest that the protein product of nybL may provide enough supply of ammonia for the amination of chorismate by anthranilate synthase [20] , encoded by nybD, during the biosynthesis of 4-aminoanthranilic acid. In the streptonigrin biosynthesis, the function of the nybL gene may be overtaken by the one of the host's primary metabolism enzymes.
After formation of 4-aminoanthranilic acid, it is then hydroxylated in the third position and decarboxylated, generating 2,6-diaminophenol (Figure 4) . The nybP gene encoding putative salicylate hydroxylase might be responsible for the hydroxylation reaction. Then, two acetoacetate units are attached to the amino groups of 2,6-diaminophenol through the action of the N-acetyltransferase encoded by the nybK gene (Figure 4) . The putative acetoacetyl-CoA synthase encoded by the nybM gene catalyses the formation of acetoacetyl-CoA from acetyl-CoA and malonyl-CoA. The NybM enzyme is likely responsible for the production of sufficient amounts of acetoacetate, which is used as a precursor in nybomycin biosynthesis. The precursor role of acetoacetate in nybomycin biosynthesis is supported by the results of the feeding experiments, which have unequivocally defined acetate as the source of the exterior carbons of the pyridone rings [16] . We speculate that after attachment of the acetoacetate units, the putative cyclase encoded by the nybN gene catalyses the closure of the pyridone rings, leading to formation of intermediate 1 (Figure 4 ). The methylation of nitrogen within the pyridone rings is likely to be catalyzed by the SAM-dependent methyltransferase encoded by nybS. We hypothesize that the next reaction in nybomycin biosynthesis is a closure of the oxazoline ring (Figure 4 ). This step might be catalyzed by the product of nybT or nybU, which code for isopenicillin N synthases (IPNS). IPNS is responsible for the biosynthesis of isopenicillin N through a bicyclization reaction-first, the formation of a C-N bond generates a β-lactam ring; then, the closure of a five-membered thiazolidine ring is accomplished by the formation of a C-S bond [21] . Sulfur and oxygen have similar properties [22] . Therefore, in a similar way to thiazolidine ring closure, IPNS could be able to catalyze the formation of a C-O bond between the carbon atom of the N-methyl group and the oxygen atom of the OH group present in intermediate 2, generating an oxazoline ring (Figure 4 ). Finally, a hydroxylation reaction takes place at C-8', possibly catalyzed by the oxidoreductase NybB, giving rise to nybomycin final structure. The compound is then secreted to the extracellular space, most likely by the membrane transporter encoded by nybV. Expression of secondary metabolite biosynthesis genes is commonly regulated by activators and repressors coded by genes that are located within the same cluster. We hypothesize that the products of nybW, nybX, and nybZ, which encode putative transcriptional regulators, might control the expression of the genes involved in nybomycin biosynthesis. In this paper we report the identification of the gene cluster encoding production of the structurally unique antibiotic nybomycin. Biological activity of nybomycin is also of particular interest as it inhibits growth of quinolone-resistant Staphylococcus aureus, dormant Mycobacterium tuberculosis, and other Gram-positive and Gram-negative bacteria [10, 14, 23] . Interestingly, nybomycin targets solely the mutant, quinolone-resistant DNA gyrase with a Ser84Leu substitution, while it is inactive against the wild-type, quinolone-sensitive form of the enzyme [10] . The mutation described thus far to cause nybomycin resistance is a reverse Leu84Ser mutation within the gyrA gene that restores quinolone sensitivity. The identification of the nybomycin cluster presented in this paper enables biosynthetic studies of nybomycin production, generation of new nybomycin derivatives, and optimization of its production as well as a nybomycin supply for further biological studies. Together, these works might help fight the development of quinolone resistance and revive quinolones as an effective class of antibiotics.
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All strains and BACs used in this work are listed in Table S2 . Escherichia coli strains were cultured in LB medium [24] . Streptomyces strains were grown on soya flour mannitol agar (MS agar) [25] for sporulation and conjugation and in liquid tryptic soy broth (TSB; Sigma-Aldrich, St. Louis, MO, USA). For secondary metabolite expression, liquid DNPM medium (40 g/L dextrin, 7.5 g/L soytone, 5 g/L baking yeast, and 21 g/L MOPS, pH 6.8) was used. The antibiotics kanamycin, apramycin and nalidixic acid were supplemented when required.
Isolation and Manipulation of DNA
BAC extraction from a Streptomyces albus subsp. chlorinus constructed genomic library (Intact Genomics, USA), DNA manipulation, E. coli transformation, and E. coli/Streptomyces intergeneric conjugation were performed according to standard protocols [24] [25] [26] . Plasmid DNA was purified with the BACMAX™ DNA purification kit (Lucigen, Middleton, WI, USA). Restriction endonucleases were used according to manufacturer's recommendations (New England Biolabs, Ipswich, MA, USA).
Metabolite Extraction and Analysis
Streptomyces strains were grown in 10 mL of TSB for 1 day, and 1 mL of each culture was used to inoculate 50 mL of production medium. Cultures were grown for 7 days at 28 • C. Metabolites were extracted with ethyl acetate from the supernatant, evaporated, and dissolved in methanol. One µL of each sample was separated using a Dionex Ultimate 3000 UPLC (Thermo Fisher Scientific, Waltham, MA, USA), a 10-cm ACQUITY UPLC ® BEH C18 column, 1.7 µm (Waters, Milford, MA, USA) and a linear gradient of 0.1% formic acid solution in acetonitrile against 0.1% formic acid solution in water from 5% to 95% in 18 min at a flow rate of 0.6 mL/min. Samples were analyzed using an amaZon speed mass spectrometer or maXis high-resolution LC-QTOF system (Bruker, USA). Data were collected and analyzed with the Bruker Compass Data Analysis software, version 4.1 (Bruker, Billerica, MA, USA). Monoisotopic mass was searched in the natural product database DNP (Dictionary of Natural Products [27]).
Nybomycin Isolation and 1 H-NMR Spectroscopy
Streptomyces albus 4N24 was grown in 30 mL of TSB for 1 day, and 1 mL of the preculture was used to inoculate 100 flasks containing 100 mL of DNPM medium. Cultures were incubated at 28 • C for 7 days. Metabolites from the supernatant were extracted as described above. The crude extract was fractionated by normal phase chromatography on a prepacked silica cartridge (Biotage, Uppsala, Sweden) using hexane, dichloromethane, ethyl acetate, and methanol as the mobile phase. Fractions containing nybomycin were detected by LC-MS analysis. They were pooled together, evaporated, and dissolved in methanol. The sample was further separated by size-exclusion chromatography on an LH 20 Sephadex column (Sigma-Aldrich, USA) using methanol as the solvent. Finally, the sample was separated by semipreparative HPLC (Dionex UltiMate 3000, Thermo Fisher Scientific, USA) using a C18 column (Synergi 10 µm, 250 × 10 mm; Phenomenex, Aschaffenburg, Germany) and a 0.1% formic acid solution in acetonitrile as the mobile phase to obtain nybomycin (0.1 mg). Individual peaks were collected and analyzed by LC-MS as described above. The 1 H-NMR spectra were recorded on a Bruker Avance 500 spectrometer (Bruker, BioSpin GmbH, Rheinstetten, Germany) at 300 K equipped with a 5 mm BBO probe using deuterated trifluoroacetic acid (Deutero, Kastellaun, Germany) as solvent containing tetramethylsilane (TMS) as a reference. The chemical shifts were reported in parts per million (ppm) relative to TMS. All spectra were recorded with the standard 1 H pulse program using 128 scans.
Genome Mining and Bioinformatics Analysis
The S. albus subsp. chlorinus genome was screened for secondary metabolite biosynthetic gene clusters using the antiSMASH [11] online tool (https://antismash.secondarymetabolites.org/#!/start) and the software Geneious 11.0.3 [28] . The DNA sequence of the nybomycin gene cluster was deposited into GenBank under accession number MH924838.
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